Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 202610.6.2026 14:30:00 CEST | Press release
LADOS connects Ondas' systems, including sensors, effectors, autonomous platforms, and command units, into one immediate operational core for integrated missions and serves as a critical systems-of-systems command-and-control layer LADOS is part of Ondas' multi-domain software architecture that includes SkyWeaver, a Palantir-powered Agentic AI layer for Multi-Domain Mission Autonomy and long-range ISR-to-assault applications The system will be officially launched at Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions WEST PALM BEACH, FL / ACCESS Newswire / June 10, 2026 / Ondas Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous drone and advanced defense technologies, today announced that it will officially launch LADOS - a Layered Autonomous Defense Operational C2 System, during Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions. LADOS serves as
Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives10.6.2026 14:30:00 CEST | Press release
Former coach to Andre Agassi joins ASE to support the Company's Agassi Intelligence platform, premium content initiatives and global growth strategy LAS VEGAS, NV / ACCESS Newswire / June 10, 2026 / Agassi Sports Entertainment Corp. (OTCID:AASP) ("ASE" or the "Company"), a sports, media, and technology platform focused on the global racket sports ecosystem and built around the iconic brands of Andre Agassi and Stefanie Graf, today announced that it has entered into a name and likeness license agreement with renowned tennis coach Darren Cahill. As a member of the team, Cahill will collaborate with ASE across a range of strategic initiatives, including the Company's previously announced Agassi Intelligence technology platform being developed in partnership with IBM, original content creation, media opportunities and other global growth initiatives designed to expand access to world-class coaching and deepen fan engagement across racket sports. Cahill, a former professional player and one
Leggett & Platt Automotive Launches New Brand Identity: Leggett Dynamics10.6.2026 12:50:00 CEST | Press release
ACCELERATES INNOVATION & GROWTH IN COMFORT, MOTION & SOFTWARE INTEGRATED SYSTEMS DETROIT, MI / ACCESS Newswire / June 10, 2026 / Leggett & Platt Automotive today announced the launch of its new brand identity, "Leggett Dynamics", and tagline "eMotion & Comfort for everyone, everywhere, every day" signaling a strategic shift to accelerate innovation and growth in comfort and motion systems for automotive, adjacent and diversified markets. Megatrend & Consumer Shifts "Leggett Dynamics creates experiences where comfort and motion feel effortless, intelligent, personalized and instinctive across all aspects of life. This positions us well in the market in terms of megatrends as well as anticipating and proactively innovating for future expectations," said Marinela Cirstea, President of Leggett Dynamics. According to Cirstea, comfort and motion are at the epicenter of converging megatrends and shifting consumers' priorities toward personalized experiences, health and wellness, plus instant
Camino Intercepts High-Grade Copper With 76.2m at 0.88% Cu Including 16.25m at 2.67% Cu and 6.82g/t Ag at Costa de Cobre in Peru; All Five Reported Drill Holes Intersect Strong Copper Mineralization10.6.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / June 10, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce the exploration results from Phase 2 of the recent drilling campaign at its Costa de Cobre project ("Costa de Cobre" or the "Project" (formerly known as "Los Chapitos"(1)) in Peru. Camino completed five drill holes along the Diva trend corridor, where drilling activities focused on the Adriana target with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. The maximum drill hole depth was 260 metres and all five drill holes intercepted strong copper mineralization and spanned a strike length of approximately 400 metres. Key highlights of recent Costa de Cobre drill holes: Adriana: DCH-131: 69.8 m @ 0.47% Cu & 4.17 g/t Ag, including 32.0 m @ 0.75% Cu & 6.50 g/t Ag, and 9.75m @ 1.25% Cu & 6.46 g/t Ag, including 3.90 m @ 2.99% Cu & 15.63 g/t Ag Adrian
From Retrofit to AI: Akkodis Strengthens Digital Innovation Through Industrial Aerospace Applications at ILA Berlin 202610.6.2026 06:45:00 CEST | Press release
At ILA Berlin 2026, Akkodis will showcase concrete applications in digital engineering, AI-driven analytics and industrial execution across the entire aerospace lifecycle - from initial digital design to real-world aerospace applications. BERLIN, DE / ACCESS Newswire / June 10, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, demonstrates how digital development, artificial intelligence and industrial execution come together to bring new solutions into aerospace applications faster at ILA Berlin 2026. Image: Akkodis at ILA Berlin 2026. Source: AkkodisIn 2026, the aerospace and defense sector is being shaped by strong growth and sustained long-term demand, supported by continued investment in innovation and next-generation technologies. At the same time, increasing pressures on efficiency, availability and sustainability are driving a shift toward solutions that can be rapidly integrated and scaled. At the center of Akkodis' presence is a n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom